98%
921
2 minutes
20
Background: Ichthyoses are a heterogeneous group of skin disorders characterized by scaling and erythema. Recognizing the variability of scale and erythema by region and ichthyosis subtype, we developed the Ichthyosis Scoring System (ISS) to quantify severity. We previously found ISS to have high inter- and intrarater reliability in evaluating photographic images. To confirm ISS clinical utility, we examined its performance at the 2022 Foundation for Ichthyosis and Related Skin Types conference.
Methods: Sixty-five participants were evaluated by 3 of 9 medical professionals trained to score ichthyosis scale and erythema using ISS. Intrarater and interrater intraclass correlation coefficients (ICC) were analyzed using one-way and two-way random effects models, respectively.
Results: Intrarater reliability was excellent (ICC = 0.931, 95% CI, 0.921-0.940) for scale and good (ICC = 0.876, 95% CI, 0.853-0.899) for erythema scoring. Compared to photo validation with excellent intrarater reliability ratings for both scale (ICC = 0.956, 95% CI, 0.925-0.974) and erythema (ICC = 0.913, 95% CI, 0.855-0.949), ISS demonstrated equivalent reliability for live use. Overall interrater reliability for 10 body sites showed excellent (ICC >0.9) and good (ICC >0.75) agreement and consistency for both scale and erythema. Palms were an exception, demonstrating moderate (ICC >0.5) interrater agreement and consistency for erythema evaluation.
Conclusions: ISS is a reliable measure of global and regional ichthyosis severity during in-person evaluations. Ease-of-use, accessibility, and content validity in both live and photographic evaluation endorse ISS as a standard for ichthyosis severity analysis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/pde.15508 | DOI Listing |
Cureus
August 2025
Department of Medical Services, Alembic Pharmaceuticals Limited, Mumbai, IND.
Introduction Upper respiratory tract infections (URTIs) are commonly encountered in primary care. Azithromycin has emerged as a preferred therapy for URTIs due to its once-daily dosing, low resistance risk, and favorable gastrointestinal tolerability. This study evaluated the real-world effectiveness and safety of azithromycin (500 mg/day) in moderate to severe acute URTIs.
View Article and Find Full Text PDFFront Immunol
September 2025
Department of Dermatology and Venereology, Medical University of Bialystok, Bialystok, Poland.
Adipose-derived mesenchymal stem cells (ADMSCs) offer a multifaceted approach to treating immune-mediated skin diseases by modulating the immune system and promoting tissue regeneration. Specifically, their ability to differentiate into multiple cell types such as keratinocytes and fibroblasts, modulate immune responses, and release growth factors and cytokines underscores their potential in treating a wide range of immune-related skin conditions. ADMSCs significantly reduced various aspects of psoriasis, including scaling, thickness, and erythema.
View Article and Find Full Text PDFJ Drugs Dermatol
September 2025
Background: Up to 90% of skin aging is caused by ultraviolet radiation, resulting in significant photodamage and clinical burden. Klotho Skin Serum, formulated with the Klotho protein for anti-aging, shows promise based on preclinical studies exploring its physiological functions and therapeutic applications.
Objective: To investigate the efficacy and safety of Klotho Skin Serum in improving visible signs of photoaging.
Biology (Basel)
August 2025
Stem Cell Laboratory, National Center for Biotechnology, Astana 010000, Kazakhstan.
Mesenchymal stem cells (MSCs) are a type of multipotent, non-hematopoietic cells of mesodermal origin. Due to their strong immunomodulatory, immunosuppressive, and regenerative potential, MSCs are used in cell therapy for inflammatory, immune-mediated, and degenerative diseases. Exosomes derived from MSCs have several advantages over MSC therapy, including non-immunogenicity, lack of infusion toxicity, ease of isolation, manipulation, and storage, cargo specificity, and the absence of tumor-forming potential and ethical concerns.
View Article and Find Full Text PDFFront Immunol
September 2025
Department of Dermatology and Venereology, Medical University of Bialystok, Bialystok, Poland.
This review presents the current knowledge on the potential of mesenchymal stem cells (MSCs) and their extracellular vesicles (EVs) in the treatment of various skin diseases such as psoriasis, atopic dermatitis, contact dermatitis, systemic sclerosis, graft-versus-host disease, alopecia areata, and systemic lupus erythematosus. MSCs can modulate the immune response and release growth factors and cytokines that promote tissue regeneration and healing and reduce inflammation. In turn, EVs' ability to transport various biological molecules, including microRNAs (miRNAs), makes them potential therapeutic agents.
View Article and Find Full Text PDF